Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants

NCT00325156 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

2590

Enrollment

INDUSTRY

Sponsor class

Conditions

Diphtheria
Tetanus
Poliomyelitis
Acellular Pertussis
Haemophilus Influenzae Type b
Diphtheria-Tetanus-aPertussis-Poliomyelitis Vaccines

Interventions

BIOLOGICAL: GSK Biologicals' combined DTPa-IPV/Hib vaccine

Sponsor

GlaxoSmithKline